ICER Sets Ceiling For Anti-Amyloid Pricing; Will Eisai And Lilly Raise The Roof?

US FDA Approvals For Both Firms’ Antibodies Expected Early 2023

 
• By Mandy Jackson
  
Workers install new roofs using mobile cranes
Eisai's earlier analysis looked at lecanemab pricing as high as $38,053 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip